论文部分内容阅读
目的：分析莫沙必利联合维酶素治疗慢性萎缩性胃炎患者的路径及效果。方法选取我院2013年8月~2014年11月收治56例慢性萎缩性胃炎患者作为临床治疗对象，采用随机数字法将56例患者均分为观察组与对照组两组，对照组28例患者单纯给予莫沙必利药物治疗方案，观察组28例患者在对照组治疗基础上联用维酶素药物治疗，对比两组患者临床疗效差异。结果经不同药物方案治疗后，观察组28例患者临床治疗总有效率达96.43%，显著高于对照组患者82.15%的临床治疗总有效率，组间疗效差异对比，<0.05，存在统计学意义。结论慢性萎缩性胃炎患者临床治疗过程中，定向给予患者莫沙必利联合维酶素药物治疗方案，可有效改善患者萎缩性胃炎病情同时，提升患者预后生活质量。“,”Objective To analyze Mosapride will benefit joint vatacoenayme path and effect for the treatment of patients with chronic gastritis. Methods Select our hospital during the period of September 2013~June 2014,56 cases of chronic atrophic gastritis patients as treatment object, adopts the method of random number 56 patients were divided into observation group,control group 28 cases with simple give,28 patients in the control group based linked with medication treatment.Results After treatment with different drugs scheme,observation group of 28 cases with clinical total effective rate of 96.43%,significantly higher than the control group total effective rate 82.15%of the patients with clinical treatment, <0.05,there is statistical significance.Conclusion In the process of the clinical treatment of patients with chronic gastritis,directional Mosapridewill give patients the joint vatacoenayme drug treatment.